Date: 12-Oct-2026
The European Medicines Agency (EMA) has published a concept paper discussing the need to develop a dedicated guideline for the clinical investigation of medicinal products intended for the treatment of inherited retinal dystrophies (IRDs).
Inherited retinal dystrophies are a group of genetic disorders that affect the retina and can lead to progressive visual impairment and blindness. The development of medicinal products for these conditions presents specific challenges in clinical research, including disease heterogeneity, variable rates of progression, patient population selection, and the identification of appropriate clinical endpoints.
The concept paper explores the need for harmonised regulatory guidance to support the design and conduct of clinical investigations for medicinal products targeting these conditions. Such guidance could help address disease-specific clinical development challenges and support the generation of robust evidence on the safety and efficacy of emerging treatments.
Key Regulatory Highlights
- Assessment of the need for dedicated clinical development guidance for inherited retinal dystrophies.
- Consideration of disease-specific challenges in clinical trial design and evaluation.
- Potential improvement in consistency across clinical investigations and regulatory assessments.
- Support for the clinical development of innovative treatments for inherited retinal disorders.
Regulatory Significance
This concept paper represents an important step in evaluating whether more specific regulatory guidance is needed for clinical development in this specialised therapeutic area. It may be relevant to pharmaceutical and biotechnology companies developing treatments for inherited retinal dystrophies, as well as regulatory affairs professionals and clinical research teams.
Source: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-investigation-medicinal-products-treatment-inherited-retinal-dystrophies_en.pdf https://www.ema.europa.eu/en/scientific-guidelines/concept-paper-need-guideline-clinical-investigation-medicinal-products-treatment-inherited-retinal-dystrophies